Lesinurad: A significant advancement or just another addition to existing therapies of gout?

Ajay Gupta, Pramod Kumar Sharma, Arup Kumar Misra, Surjit Singh

Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India

ABSTRACT

Gout is a metabolic disorder that usually presents as recurrent episodes of acute arthritis due to deposition of crystals in joints and cartilages. Despite the availability of several drugs for gout, its management is still less than adequate. There is always a search for newer, safer, and more potent urate-lowering therapies for treating patients inadequately controlled with available drugs. Lesinurad in combination with a xanthine oxidase inhibitor provides an effective mode of therapy in the management of hyperuricemia associated with gout. Lesinurad is a selective uric acid transporter 1 (URAT1) inhibitor. URAT1 is responsible for the majority of uric acid absorption from kidneys to the circulation. Lesinurad was granted marketing approval based on three randomized, double-blind, placebo-controlled; phase III clinical trials. It is devoid of interaction with organic anion transporters (OATs) such as OAT1 and 3, responsible for drug–drug interactions, an undesirable property associated with probenecid. On-going research is more focused on reducing inflammation consequent to deposition of crystals rather than production and excretion of urate. Various targets are being explored, and interleukin-1 beta inhibition seems to be one of the most promising approaches.

Key words: Hyperuricemia, lesinurad, uric acid transporter 1, xanthine oxidase inhibitor

INTRODUCTION

Gout is a metabolic disorder wherein fundamental biochemical abnormality is hyperuricemia. It clinically presents as recurrent episodes of acute arthritis due to deposition of monosodium urate crystals in joints and cartilage. The crystallization of uric acid depends on several factors such as temperature, pH, concentration of cations, the level of articular dehydration, and the presence of such nucleating agents as nonaggregated proteoglycans, insoluble collagens, and chondroitin sulfate. In comparison to its hypoxanthine and xanthine precursors, uric acid is relatively insoluble. Low temperature favors crystal deposition making peripheral regions of the body more susceptible. Urate crystals through toll-like receptor pathway lead to activation of the NALP3 inflammasome with the release of proinflammatory cytokines including interleukin-1 beta (IL-1β) and tumor necrosis factor (TNF)-α. These cytokines, in turn, cause endothelial activation and attraction of neutrophils to the site of inflammation.
Urate is the end product of purine metabolism. It is produced from xanthine and hypoxanthine by the action of the enzyme xanthine oxidase. Urate is excreted primarily through kidneys. Hyperuricemia can occur either due to overproduction or underexcretion by the kidneys, the latter being more common.

The recommended serum uric acid (SUA) target to durably improve the signs and symptoms of gout is <6 mg/dL. However, a target of SUA <5 mg/dL is recommended for greater disease severity, such as patients with tophaceous gout.

Agents used to treat hyperuricemia can be grouped into three categories based on their mechanism of action: Drugs that decrease uric acid production (xanthine oxidase inhibitors [XOIs]; allopurinol and febuxostat); drugs that increase urinary uric acid excretion (probenecid); and drugs that enzymatically degrade excess circulating uric acid (pegloticase).

Newer targets for treating gout have been persistently explored because none of the currently used drugs can be called ideal. This is primarily because of ineffectiveness in achieving target SUA levels and adverse effects associated with available therapies. Considering under-excretion of uric acid as major cause of hyperuricemia, in recent years important urate transport proteins such as the human uric acid transporter 1 (URAT1) and the fructose transporter SLC2A9 have been characterized. Lesinurad, a newer drug to treat chronic refractory gout by targeting the URAT1 transporter, has been approved recently by the US Food and Drug Administration in combination with an XOI.

Lesinurad, a selective uric acid reabsorption inhibitor (URAT1), is a 12-transmembrane domain containing protein found in the apical membrane of proximal tubular epithelial cells and transports urate in exchange for Cl− or organic anions. The antiuricosuric agents lactate, pyrazinoate, and nicotinate can serve as a substrate for the antiporter activity of URAT1 to increase uric acid reabsorption. On the other hand, URAT1 is inhibited by the classical uricosuric agents benz bromarone, probenecid, and losartan.

Uric acid is freely filtered in the kidney at the glomerulus and enters the proximal tubule where more than 90% is reabsorbed back into the bloodstream through URAT1.

Any uric acid that is not reabsorbed moves to the distal part of the nephron and is excreted in the urine. In the majority of patients with gout, hyperuricemia is caused by inefficient renal excretion of uric acid. Lesinurad is a selective uric acid reabsorption inhibitor that inhibits the URAT1; thus, increases uric acid excretion. Lesinurad also inhibits organic anion transporter 4 (OAT4), an URAT1 involved in diuretic-induced hyperuricemia.

XOIs such as allopurinol and febuxostat act by reducing the production of uric acid, primarily in the liver and intestine. Targeting both excretion and production of uric acid provide a dual mechanism approach to effectively lower SUA levels. This combination approach is considered ideal for those who do not achieve SUA targets on a XOI alone, and in patients with uncontrolled gout as evident by continuing disease activity.

Lesinurad has rapid oral absorption and is highly plasma protein bound. Approximately, half of the oral dose is cleared via CYP2C9 metabolism; therefore, caution is required when it is administered with moderate CYP2C9 inhibitors (e.g., fluconazole, amiodarone). Lesinurad has no relevant effect on anionic or cationic transporters such as OAT1 and OAT3 which are mainly responsible for drug–drug interactions associated with probenecid.

**CLINICAL TRIALS**

The regulatory approval of lesinurad is based on three randomized, double-blind, placebo-controlled, phase III clinical trials - CLEAR 1, CLEAR 2, and CRYSTAL.

Two replicate studies (CLEAR 1, CLEAR 2) evaluated lesinurad (200 or 400 mg oral, once daily) in combination with allopurinol versus allopurinol + placebo in subjects with gout aged 18–85 years. Subjects were required to be on stable allopurinol doses ≥300 mg (≥200 mg for moderate renal impairment), have SUA ≥6.5 mg/dL at screening, and history of ≥2 gout flares in the prior 12 months. The primary endpoint was the proportion of subjects meeting SUA target of <6.0 mg/dL by 6 months. Lesinurad (200 or 400 mg) in combination with allopurinol achieved SUA target at 6 months by ~2–2.5-fold compared to allopurinol alone.

Similarly, the CRYSTAL study evaluated lesinurad in combination with febuxostat against febuxostat monotherapy in patients with tophaceous gout. Not only the combination therapy resulted in the higher proportion of patients achieving SUA <5 mg/dL at 6 months but also achieved greater tophus area resolution.

**DOES LESINURAD HAS AN EDGE OVER EXISTING URICOSURICS?**

- OAT1 and OAT3 are organic transporters involved in the movement of uric acid through the basolateral membrane
to the circulation. Many drugs such as tenofovir and emtricitabine, reverse transcriptase inhibitors depend on OAT1 and OAT3 for clearance through kidneys. Existing urate lowering drugs such as probenecid and benz bromarone inhibit OAT1 and OAT3 thus posing a significant problem of drug–drug interactions. Lesinurad devoid of interaction with OAT1 or OAT3, is a major breakthrough in solving this hurdle of clinically relevant drug–drug interactions.

- It has been shown in animal [26] as well as clinical [27] studies that no unfavorable pharmacokinetic interaction or interference with urinary excretion exists between lesinurad and XOIs such as allopurinol or oxypurinol and febuxostat. Co-administration of lesinurad and XOIs thus could safely be used to accelerate urate reduction in gout patients.
- Continued use of allopurinol at suboptimal doses in patients with renal insufficiency could worsen renal failure, or sometimes may precipitate fatal hypersensitivity syndrome. [28] Under-dosing for fear of side-effects is clearly a hindrance in achieving therapeutic goal. Combining lesinurad at a fixed dose of 200 mg/day with XOIs helps in controlling hyperuricemia more effectively. Evidence is available that effective treatment of hyperuricemia may improve renal functions. Introduction of lesinurad has effectively addressed the issue of allopurinol under dosing.
- It also inhibits OAT4, a URAT1 involved in diuretic-induced hyperuricemia. In future, it might be indicated to prevent hyperuricemia usually associated with prolonged diuretic (loop or thiazides) therapy.

**THERAPIES IN PIPELINE**

Further research for the management of gout is directed towards limiting the inflammatory events that are initiated by the deposition of urate crystals. Various specific targets in the inflammatory pathway of gout are:

- NALP3 inflammasome and IL-1β [5-7]
- Complement C5b-9 membrane attack complex, [29] agonism of phagocyte melanocortin receptor 3 (shown to be a direct peripheral target of adrenocorticotropic hormone), the chemokines CXC1 and CXCL8, TNF-α. [30]

Among above targets, IL-1β neutralization appears to play a central role in the control of inflammatory events. Both animal [31] and clinical [32] studies have demonstrated the effect of IL-1β inhibition by anakinra in gout. Based on the above findings, biologics against IL-1β such as canakinumab and rilonacept were evaluated for its effect in patients of acute gout or those who were intolerant to existing therapies. Both the agents demonstrated a significant improvement in the patients’ symptoms such as gout flares, and pain as compared to placebo or corticosteroids. [25] Further clinical trials on a large scale with IL-1β inhibitors will help in establishing their role in patients of gout.

**CONCLUSION**

Apprehensions and confusions about how to use existing drugs in the management of gout is a perpetual issue, and merely addition of new drugs is not sufficient to resolve these misconceptions. Availability of a new therapy always offers an opportunity for us to revisit the treatment strategies to improve outcome in this highly treatable disease. Concerns clearly warrant additional treatment options for patients with gout who are unable to achieve and sustain recommended SUA levels with currently available therapies. Lesinurad inhibits URAT1, increases uric acid excretion and thereby lowers SUA. Lesinurad, when used in combination with an XOIs (allopurinol or febuxostat), targets both aspects of SUA regulation (production and excretion) providing a dual mechanism approach to more effectively lower SUA.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Tausche AK, Jansen TL, Schröder HE, Aringer M, Müllner-Ladner U. Gout – current diagnosis and treatment. Dtsch Arztebl Int 2009;106:549-55.
2. Borazan NH, Fürst DE. Nonsteroidal Anti-inflammatory drugs, disease modifying antirheumatic drugs, nonopioide analgesics, & drugs used in gout. In: Katzung BG, Trevor AJ. editors. Basic and Clinical Pharmacology. 13th ed. New Delhi: Mcgraw-Hill Education (India) Private Limited; 2015, p. 634.
3. Choi HK, Mount DB, Beginato AM; American College of Physicians; American Physiological Society. Pathogenesis of gout. Ann Intern Med 2005;143:499-516.
4. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician 1999;59:925-34.
5. Martiñon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.
6. Pétrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: A danger sensing complex triggering innate immunity. Curr Opin Immunol 2007;19:615-22.
7. Dalbeth N, Haskard DO. Inflammation and tissue damage in crystal deposition diseases. Curr Opin Rheumatol 2005;17:314-8.
8. Richette P, Doherty M, Paschel B, Barskova V, Becce F, Coyfish M, et al. SAT0531 updated eular evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases. 2014 Jun 1;73(Suppl 2):783.
9. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1341-46.
10. Jordan KM, Cameron JS, Smith M, Zhang W, Doherty M, Seck J, et al. British Society for rheumatology and British Health Professionals in rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46:1372-4.
11. Unger S, Tausche AK, Kopprasch S, Bornstein SR, Aringer M, Grässler J. Molecular basis of primary renal hyperuricemia: Role of the human urate transporter hURAT1. Z Rheumatol 2007;66:556, 58-61.

12. Graessler J, Grässler A, Unger S, Kopprasch S, Tausche AK, Kuhlisch E, et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 2006;54:292-300.

13. ZURAMPIC (Lesinurad) Approved by US FDA for Patients with Gout; 22 December, 2015. Available from: https://www.astrazeneca.com/media-centre/press-releases/2015/ZURAMPIC-lesinurad-approved-by-US-FDA-for-patients-with-gout-22122015.html. [Last cited on 2016 Jun 15].

14. ZURAMPIC. EPAR Summary for the Public. London: European Medical Agency; 2016. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Summary_for_the_public/human/003932/WC500203068.pdf. [Last cited on 2016 Jun 16].

15. Pascual E, Perdiguero M. Gout, diuretics and the kidney. Ann Rheum Dis 2006;65:981-2.

16. Enomoto A, Kimura H, Chiarroengdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002;417:447-52.

17. Takahashi T, Tsuchida S, Oyamada T, Ohno T, Miyashita M, Saito S, et al. Recurrent URAT1 gene mutations and prevalence of renal hypouricemia in Japanese. Pediatr Nephrol 2005;20:576-8.

18. Ichida K, Hosoyamada M, Kamatani N, Kanitsujii S, Hisatome I, Shibasaki T, et al. Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese. Clin Genet 2008;74:243-51.

19. Reginato AM, Mount DB, Yang I, Choi HK. The genetics of hyperuricemia and gout. Nat Rev Rheumatol 2012;8:610-21.

20. Vázquez-Mellado J, Jiménez-Vaca AL, Cuevas-Covarrubias S, Alvarado-Romano V, Pozo-Molina G, Burgos-Vargas R. Molecular analysis of the SLCA22A12 (URAT1) gene in patients with primary gout. Rheumatology (Oxford) 2007;46:215-9.

21. Handler J. Managing hypertensive patients with gout who take thiazide. J Clin Hypertens (Greenwich) 2010;12:731-5.

22. Lesinurad in Combination With a Xanthine Oxidase Inhibitor for Treatment of Hyperuricemia Associated With Gout. Ardea Biosciences; 2015. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM467951.pdf. [Last cited on 2016 Jun 15].

23. Saag KG, Adler S, Bhakta N, Fung M, Kopicko J, Storgard C, et al. Lesinurad, a novel selective uric acid reabsorption inhibitor, in two phase III clinical trials: Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders (CLEAR 1 and 2). Arthritis Rheum 2014;66:3533-4.

24. Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, et al. SAT0329 Lesinurad, a novel selective uric acid reabsorption inhibitor, in combination with febuxostat, in patients with tophaceous gout: The crystal phase III clinical trial. Ann Rheum Dis 2015;74 Suppl 2:778.

25. Burns CM, Wortmann RL. Gout therapeutics: New drugs for an old disease. Lancet 2011;377:165-77.

26. Yang X, Dick R, Borges V, Yazdani N, Green A, Manhard K, et al. Evaluation of drug-drug interaction potential between RDEA594, allopurinol and febuxostat in preclinical species. Arthritis Rheum. 2009;60:S412-3.

27. Yeh LT, Shen Z, Kerr B, Tamai I, Hingorani V, Ong V, et al. RDEA594, a potent URAT1 inhibitor without affecting other important renal transporters OAT1 and OAT3. Ann Rheum Dis. 2009;68(Suppl 3):320.

28. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.

29. Tramontini N, Huber C, Liu-Bryan R, Terkeltaub RA, Kilgore KS. Central role of complement membrane attack complex in monosodium urate-crystal-induced neutrophilic rabbit knee synovitis. Arthritis Rheum 2004;50:2633-9.

30. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther 2006;8 Suppl 1:S53.

31. So A, De Smelt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28.

32. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009;68:1613-7.